AVBPArriVent BioPharma, Inc.
Is it safe?
Big price swings. That is the only one of 6 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Large price swings, high volatility. Worst drawdown -58% · now 51% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AVBP take a bad year?
The deepest fall in AVBP's price history on file is −58%; it is 51% below its high today.
Worst drawdown on file · −51% today
- Annualised volatility
- 65%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $373M
- Operating profit, trailing twelve months
- −$176M
- Annualised volatilitytwo years of daily moves
- 65%
- Worst drawdown on file
- −58%
- Below its 52-week high
- 51%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry